Actively Recruiting
Angiogenic Function at Normal Term on Placenta
Led by Centre Hospitalier Intercommunal Creteil · Updated on 2022-12-21
750
Participants Needed
1
Research Sites
N/A
Total Duration
On this page
Sponsors
C
Centre Hospitalier Intercommunal Creteil
Lead Sponsor
I
Institut National de la Santé Et de la Recherche Médicale, France
Collaborating Sponsor
AI-Summary
What this Trial Is About
This research aims to better understand how certain factors that control blood vessel growth, such as placenta growth factor (PlGF) and soluble FMS-like tyrosine kinase-1 (sFlt-1), are expressed by trophoblastic cells in healthy placentas from normal pregnancies at term. The study also seeks to explore how these factors relate to placental function and differentiation, which are important for a healthy pregnancy. The study involves observing placentas from scheduled cesarean deliveries after 37 weeks of pregnancy. Researchers will examine the gene and protein levels of these angiogenic factors in the placental tissue. Additionally, they may expose these healthy placentas to various chemical compounds to study their effects on placental biology and to explore potential therapeutic targets for pregnancy complications like pre-eclampsia and intrauterine growth restriction. Participants will be involved through collection of placental tissue during cesarean delivery. Researchers will measure levels of placental angiogenic factors on the day of collection and follow up on specific protein levels the next day. The study includes laboratory tests and tissue analysis to assess placental function and angiogenic factor expression, aiming to improve understanding of placental health and its disorders during pregnancy.
CONDITIONS
Brief Title
ANgiogenic Function at NOrmal TErm on Placenta
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Pregnancies with scheduled cesarean delivery after 37 weeks of amenorrhea
- Strictly normal pregnancies
- Pregnancies complicated by gestational diabetes, insulin-treated or not
- Pregnancies complicated due to pregnancy cholestasis
- Spontaneous or in vitro fertilization (IVF) / Intracytoplasmic sperm injection (ICSI) pregnancies with or without oocyte donation
You will not qualify if you...
- Patient's opposition to participate
- Age less than 18 years old
- Women under the protection of justice
- Multiple pregnancy
- Known major fetal malformation
- Pre-eclampsia and intrauterine growth retardation
- Placental insertion anomaly
- Type 1 diabetes
- HIV-positive or hepatitis C virus (HCV) infection regardless of viral load
- Patient in labor at the time of cesarean section
- Use of medications during pregnancy that may affect trophoblast biology (immunomodulators for autoimmune diseases, anti-rejection drugs for transplant patients)
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Your Study Journey
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - 1 day
Participants provide placental samples at the time of scheduled cesarean delivery for analysis of angiogenic factors.
1 visit (in-person at delivery)
Duration - Up to 1 day post-delivery
Participants' placental samples are observed and analyzed to understand gene and protein expression related to placental function and pregnancy pathologies.
1 visit (in-person follow-up up to day 1)
Trial Site Locations
Total: 1 location
1
Centre Hospitalier Intercommunal de Créteil
Créteil, France, 94000
Actively Recruiting
Research Team
C
camille JUNG, MD
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
0
Similar Trials
Frequently Asked Questions
Have more questions? Get in touch with our team for quick support
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here